Raltegravir, maraviroc, etravirine: An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

AIDS

Volumn 24, Issue 6, 2010, Pages 924-928

  Nozza, Silvia ^a   Galli, Laura ^a   Visco, Francesca ^a   Soria, Alessandro ^a   Canducci, Filippo ^b   Salpietro, Stefania ^a   Gianotti, Nicola ^a   Bigoloni, Alba ^a   Torre, Liviana Della ^a   Tambussi, Giuseppe ^a   Lazzarin, Adriano ^a,b   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL THERAPY; ANUS CANCER; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEPATITIS C; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; INTERVERTEBRAL DISK DEGENERATION; MUTATION; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; TREATMENT FAILURE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOHEXANES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; TRIAZOLES; VIRAL LOAD;

EID: 77949551533     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283372d76     Document Type: Article

References (18)

1. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
2. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
3. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
4. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48
5. HIV Drug Resistance Database Stanford University, http://hivdb.stanford. edu
6. Vingerhoets J, Peeters M, Azijn H, Tambuyzer L, Hoogstoel A, Nijs S, et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multi-variate analysis on the pooled DUET-1 and DUET-2 clinical trial data. Antiv Ther 2008; 13 (Suppl 3):A26.
7. European Medicine Agency (EMEA). Intelence. Marketing authorisation 28 Aug 2008.
8. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial. XVII International AIDS Conference, Mexico City, 3-8 August 2008, Abstract THAB0406.
9. Florence E, De Wit S, Castagna A, Ribera E, Hill A, Vanaken H, et al. Antiretroviral treatment use and HIV RNA suppression rates for 941 European patients in the Etravirine Early Access Programme. Abstract P036.
10. Imaz A, Villar de Saz A, Rivas MA, Curvan A, Caballero E, Falco V, et al. Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV-1 infected patients. 9th International Congress on HIV and Drug TherapyinHIV Infection. Glasgow9-13November 2008, Abstract P040.
11. Almasi F, Krivine A, Compangocci A, Silberman B, Belaebi L, Solman D. Efficacy and tolerance of maraviroc with MK-0518, boosted TMC 114, TMC-125 in heavily pretreated CCR5-posi-tive patients. 9th International Congress on HIV and Drug Therapy in HIV Infection. Glasgow 9-13 November 2008, Abstract P046.
12. Thuret I, Tamalet C, Reliquet V, Firtion V, Frange P, Tricoire J, et al. Raltegravir in children and adolescents: the French expanded access program. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8-11 2009. Abstract 873.
13. Capetti AF, Piconi S, Landonio S, Rizzardini G, Perno CF. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? J Acquir Immune Defic Syndr 2009; 50:233-234.
14. Saag M, Ive P, Heera J, Tawadrous M, DeJesus E, Clumeck N, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/lamivudine), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 22-25, 2007. Sydney. Abstract WESS104.
15. Lennox J, DeJesus E, Lazzarin A, et al. STARTMRK, a phase III study of the safety and efficacy of raltegravir-based vs. efavirenz-based combination therapy in treatment-naive HIV-infected patients. 48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC). October 25-28, 2008. Washington, DC. Abstract H-896O.
16. Gallant JE, Winston JA, De Jesus E, Pozniak AL, Chen SS, Cheng AK, et al. The 3-year renal safety of a tenofovir disoproxil-fumarate vs. a thymidine analogue-containing regimen in anti-retroviral näive patients. AIDS 2008; 22:2155-2163.
17. Prevalence of anemia and correlations with biomarkers and specific antiretroviral regimens in 9690 human immunodeficiency virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin 2007; 2:343-355.
18. Cooper D, Steigbigel R, Lennox J, Grinsztejn B, Markowitz M, Sklar P, et al. Review of cancer incidence in raltegravir clinical trials. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8-11 2009. Abstract 859.